+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Tuberculosis Diagnostics Market - Global Forecast 2026-2032- Product Image
Tuberculosis Diagnostics Market - Global Forecast 2026-2032- Product Image
Sale

Tuberculosis Diagnostics Market - Global Forecast 2026-2032

  • Report

  • 197 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4985929
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Tuberculosis Diagnostics Market is projected to reach USD 2.59 Billion in 2026. It is expected to continue growing at a CAGR of 6.77%, reaching USD 3.88 Billion by 2032.

Tuberculosis diagnostics are central to global TB control because early, accurate detection determines how quickly patients receive effective therapy and how rapidly transmission chains are interrupted. According to the World Health Organization, an estimated 10.8 million people developed TB in 2023, while 1.25 million people died from the disease, underscoring the need for scalable tuberculosis testing across high-burden and low-incidence settings.

The market spans sputum smear microscopy, mycobacterial culture, molecular diagnostics, line probe assays, drug-susceptibility testing, interferon-gamma release assays, lateral flow urine lipoarabinomannan testing for eligible populations, and digital chest X-ray supported by computer-aided detection. Demand is being shaped by national TB elimination programs, antimicrobial resistance surveillance, decentralized molecular testing, and the push to close diagnostic gaps for drug-resistant tuberculosis and pediatric, extrapulmonary, and HIV-associated TB.

Transformative Shifts in the Tuberculosis Diagnostics Landscape

The tuberculosis diagnostics landscape is shifting from centralized, microscopy-led workflows toward faster, more decentralized, and digitally connected testing models. WHO-recommended rapid diagnostics, including nucleic acid amplification tests, are increasingly prioritized as initial tests because they can detect Mycobacterium tuberculosis complex and key rifampicin-resistance markers far faster than culture-based methods.

At the same time, health systems are expanding case-finding beyond symptomatic clinic presentation. Digital radiography, targeted screening in high-risk populations, integrated TB-HIV services, and drug-resistance testing are changing procurement priorities. These shifts favor diagnostics that combine accuracy, operational simplicity, connectivity, and suitability for district laboratories, mobile screening units, prisons, mines, refugee settings, and primary care facilities.

Cumulative Impact of Artificial Intelligence on TB Diagnostics

Artificial intelligence is having a cumulative impact across the TB diagnostic pathway by improving screening throughput, triage accuracy, workflow prioritization, and surveillance intelligence. WHO guidance supports computer-aided detection software for interpreting chest radiographs in TB screening and triage among people aged 15 years and older, enabling programs to extend radiology capacity where trained readers are limited.

AI does not replace confirmatory microbiological testing, culture, or drug-susceptibility testing, but it strengthens the front end of the diagnostic cascade. When paired with digital X-ray, molecular confirmation, laboratory information systems, and geospatial analytics, AI can reduce missed cases, prioritize high-risk individuals for nucleic acid amplification testing, support quality assurance, and improve program monitoring. The strongest adoption opportunities are in settings where algorithms are locally validated, bias is monitored, data governance is clear, and results are linked to rapid treatment initiation.

Key Regional Insights for Tuberculosis Diagnostics

Asia-Pacific remains the center of global TB diagnostic demand, led by high-burden countries and large public-sector testing networks. India, China, Indonesia, the Philippines, and Vietnam continue to drive investment in molecular platforms, digital chest X-ray, sample transport systems, and drug-resistance detection, supported by national TB strategies aligned with WHO recommendations. North America is characterized by low-incidence TB control, strong laboratory quality systems, immigration and congregate-setting screening, latent TB infection management, and adoption of advanced molecular and immunological testing.

Latin America is expanding access to rapid molecular diagnostics while addressing uneven laboratory coverage across urban, rural, and border communities, with Brazil and Mexico playing important roles in public-sector TB testing scale-up. Europe combines low-incidence elimination strategies in Western Europe with heightened attention to migration-linked screening, cross-border surveillance, and drug-resistant TB risks in parts of Eastern Europe. The Middle East is shaped by migrant-worker screening, hospital-based diagnostics, and GCC investments in public health infrastructure. Africa remains a critical region because high TB-HIV burden, delayed diagnosis, and limited laboratory access create substantial demand for decentralized nucleic acid amplification testing, urine lipoarabinomannan testing for eligible people with HIV, mobile radiography, and connected surveillance systems.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN countries are strengthening TB diagnostic capacity through public-sector procurement of rapid molecular systems, expanded community screening, and donor-supported laboratory modernization. The region’s large population base, cross-border mobility, and persistent drug-resistance concerns create demand for connected, affordable, and field-ready testing platforms that can support case detection across dense urban areas, islands, and remote communities.

The GCC emphasizes pre-employment and residency-linked screening, high-quality hospital diagnostics, and digital health integration as part of broader infectious disease control. The European Union prioritizes TB elimination, quality-assured laboratory networks, and coordinated surveillance, while BRICS economies are pivotal because Brazil, Russia, India, China, and South Africa combine large testing volumes with domestic manufacturing ambitions, high-burden settings, and strong policy influence. G7 markets focus on innovation, regulatory quality, latent TB management, and low-incidence TB control, whereas NATO countries increasingly view infectious disease detection, laboratory readiness, and resilient supply chains as part of broader health security planning.

Key Country Insights for Major Tuberculosis Diagnostics Markets

The United States and Canada focus on targeted testing, latent TB infection management, public health laboratory capacity, and rapid detection of drug resistance, particularly among foreign-born populations and people with defined exposure risks. Mexico and Brazil are expanding access to molecular testing while addressing regional disparities, high-risk urban populations, and continuity between screening, confirmation, and treatment initiation. In Europe, the United Kingdom, Germany, France, Italy, and Spain emphasize low-incidence control, migrant screening, contact investigation, and advanced laboratory diagnostics, while Russia remains a significant market for drug-resistant TB detection, culture capacity, and surveillance.

China and India are the most influential country markets because of scale, national TB programs, domestic diagnostic manufacturing, and large public-sector procurement, with both countries investing in faster detection and broader drug-resistance testing. Japan, Australia, and South Korea maintain advanced diagnostic infrastructure, strong regulatory systems, and emphasis on screening high-risk populations, older adults, contacts, and foreign-born communities. Across these countries, the competitive advantage increasingly favors solutions that combine WHO-aligned performance, affordability, connectivity, reliable service support, biosafety compliance, and compatibility with national reporting systems.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize WHO-recommended diagnostic categories, local clinical validation, and product designs that meet the operational realities of high-burden settings. Successful strategies include decentralized molecular testing, robust maintenance models, uninterrupted cartridge and reagent availability, low-infrastructure operating options, biosafety-aware sample handling, and integration with electronic TB registers.

Organizations should also invest in partnerships with national TB programs, global health funders, private laboratory chains, community screening initiatives, and radiology networks. AI-enabled screening tools should be deployed with transparent performance evidence, bias monitoring, cybersecurity safeguards, local validation, and clear referral pathways for confirmatory testing. Manufacturers that align pricing, training, logistics, connectivity, and quality assurance with public health goals will be better positioned to win long-term procurement contracts and improve patient outcomes.

Research Methodology

This executive summary is based on secondary research from authoritative public health sources, including WHO tuberculosis guidance, global TB surveillance data, national TB program priorities, regulatory trends, peer-reviewed evidence on diagnostic performance, and publicly available information on molecular testing, radiography, AI-enabled screening, and drug-susceptibility testing.

The methodology emphasizes triangulation across epidemiology, technology adoption, policy direction, procurement behavior, laboratory infrastructure, and regional disease burden. Insights were evaluated for relevance to tuberculosis diagnostics, including active TB detection, drug-resistant TB identification, latent TB testing, screening, triage, laboratory workflow, and digital reporting. No unsupported market-size, market-share, or forecasting claims are used; conclusions are grounded in verified disease burden, guideline evolution, and observable diagnostic deployment trends.

Conclusion

Tuberculosis diagnostics are moving into a more rapid, decentralized, and intelligence-enabled era. The combination of molecular testing, digital radiography, AI-supported screening, drug-resistance detection, and connected surveillance is reshaping how health systems find TB, confirm infection, and initiate effective treatment.

The strongest opportunities will emerge where diagnostic technologies are affordable, quality assured, locally validated, and embedded in patient-centered care pathways. As countries work toward TB elimination targets, industry leaders that support equitable access, reliable supply, and measurable public health impact will define the next phase of progress in the global tuberculosis diagnostics market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Tuberculosis Diagnostics Market, by Product
7.1. Introduction
7.2. Consumables
7.2.1. Kits
7.2.2. Reagents
7.3. Instruments
8. Tuberculosis Diagnostics Market, by Technology
8.1. Introduction
8.2. Molecular
8.2.1. Genotypic Assays
8.2.2. Nucleic Acid Amplification Tests
8.3. Nonmolecular
8.3.1. Imaging
8.3.2. Immunological Assays
9. Tuberculosis Diagnostics Market, by Test Type
9.1. Introduction
9.2. Detection Test
9.2.1. Blood Tests
9.2.2. Culture-Based Tests
9.2.3. Molecular Tests
9.2.4. Skin Tests
9.2.5. Smear Microscopy
9.3. Drug Susceptibility Testing
9.3.1. Molecular Dst
9.3.2. Phenotypic Dst
10. Tuberculosis Diagnostics Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Hospitals
10.4. Reference Laboratories
11. Tuberculosis Diagnostics Market, by Application
11.1. Introduction
11.2. Active Tb
11.2.1. Extrapulmonary Tb
11.2.2. Pulmonary Tb
11.3. Latent Tb
12. Tuberculosis Diagnostics Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Tuberculosis Diagnostics Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Tuberculosis Diagnostics Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abbott Laboratories
16.2. Becton, Dickinson and Company
16.3. Bio-Rad Laboratories, Inc.
16.4. Biocartis Group NV
16.5. bioMérieux SA
16.6. Bruker Corporation.
16.7. Creative Diagnostics
16.8. Danaher Corporation
16.9. DiaSorin S.p.A.
16.10. F. Hoffmann-La Roche Ltd.
16.11. Fujifilm Holdings Corporation
16.12. Hologic, Inc.
16.13. Kindstar Globalgene Technology, Inc.
16.14. Lionex GmbH
16.15. Molbio Diagnostics Limited
16.16. QIAGEN N.V.
16.17. Revvity, Inc.
16.18. SD Biosensor, Inc.
16.19. Seegene Inc.
16.20. Siemens Healthineers AG
16.21. Thermo Fisher Scientific Inc.
16.22. Zhejiang Di'an Diagnostics Technology Co., Ltd.
List of Figures
FIGURE 1. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
FIGURE 7. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 9. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CONSUMABLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CONSUMABLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CONSUMABLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL REAGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL REAGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL REAGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL MOLECULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL MOLECULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL MOLECULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL GENOTYPIC ASSAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL GENOTYPIC ASSAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL GENOTYPIC ASSAYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL NUCLEIC ACID AMPLIFICATION TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL NUCLEIC ACID AMPLIFICATION TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL NUCLEIC ACID AMPLIFICATION TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL NONMOLECULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL NONMOLECULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL NONMOLECULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL IMAGING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL IMAGING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL IMAGING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL IMMUNOLOGICAL ASSAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL IMMUNOLOGICAL ASSAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL IMMUNOLOGICAL ASSAYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL DETECTION TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL DETECTION TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL DETECTION TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL BLOOD TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL BLOOD TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL BLOOD TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL CULTURE-BASED TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL CULTURE-BASED TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL CULTURE-BASED TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL MOLECULAR TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL MOLECULAR TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL MOLECULAR TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL SKIN TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL SKIN TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL SKIN TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL SMEAR MICROSCOPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL SMEAR MICROSCOPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL SMEAR MICROSCOPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL DRUG SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL DRUG SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL DRUG SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL MOLECULAR DST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL MOLECULAR DST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL MOLECULAR DST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL PHENOTYPIC DST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL PHENOTYPIC DST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL PHENOTYPIC DST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL ACTIVE TB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL ACTIVE TB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL ACTIVE TB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL EXTRAPULMONARY TB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL EXTRAPULMONARY TB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL EXTRAPULMONARY TB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL PULMONARY TB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL PULMONARY TB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL PULMONARY TB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL LATENT TB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL LATENT TB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL LATENT TB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2017-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2017-2032 (USD MILLION)
TABLE 99. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 101. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 102. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 103. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2017-2032 (USD MILLION)
TABLE 104. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2017-2032 (USD MILLION)
TABLE 105. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2017-2032 (USD MILLION)
TABLE 108. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 110. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2017-2032 (USD MILLION)
TABLE 111. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 113. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 114. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 115. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2017-2032 (USD MILLION)
TABLE 116. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2017-2032 (USD MILLION)
TABLE 117. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 118. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2017-2032 (USD MILLION)
TABLE 119. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2017-2032 (USD MILLION)
TABLE 120. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 121. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 122. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2017-2032 (USD MILLION)
TABLE 123. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 125. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 126. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 127. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2017-2032 (USD MILLION)
TABLE 128. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2017-2032 (USD MILLION)
TABLE 129. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 130. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2017-2032 (USD MILLION)
TABLE 131. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2017-2032 (USD MILLION)
TABLE 132. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 133. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 134. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2017-2032 (USD MILLION)
TABLE 135. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 136. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 137. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 138. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 139. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2017-2032 (USD MILLION)
TABLE 140. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2017-2032 (USD MILLION)
TABLE 141. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 142. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2017-2032 (USD MILLION)
TABLE 143. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2017-2032 (USD MILLION)
TABLE 144. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 145. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 146. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2017-2032 (USD MILLION)
TABLE 147. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 148. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 149. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 150. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 151. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2017-2032 (USD MILLION)
TABLE 152. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2017-2032 (USD MILLION)
TABLE 153. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 154. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2017-2032 (USD MILLION)
TABLE 155. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2017-2032 (USD MILLION)
TABLE 156. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 157. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 158. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2017-2032 (USD MILLION)
TABLE 159. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 160. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 161. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 162. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 163. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 164. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2017-2032 (USD MILLION)
TABLE 165. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2017-2032 (USD MILLION)
TABLE 166. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 167. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2017-2032 (USD MILLION)
TABLE 168. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2017-2032 (USD MILLION)
TABLE 169. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 170. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 171. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2017-2032 (USD MILLION)
TABLE 172. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 173. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 174. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 175. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 176. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2017-2032 (USD MILLION)
TABLE 177. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2017-2032 (USD MILLION)
TABLE 178. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 179. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2017-2032 (USD MILLION)
TABLE 180. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2017-2032 (USD MILLION)
TABLE 181. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 182. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 183. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2017-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2017-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2017-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2017-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2017-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2017-2032 (USD MILLION)
TABLE 196. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 197. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 198. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 199. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 200. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2017-2032 (USD MILLION)
TABLE 201. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2017-2032 (USD MILLION)
TABLE 202. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 203. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2017-2032 (USD MILLION)
TABLE 204. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2017-2032 (USD MILLION)
TABLE 205. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 206. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 207. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2017-2032 (USD MILLION)
TABLE 208. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 209. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 210. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 211. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 212. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2017-2032 (USD MILLION)
TABLE 213. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2017-2032 (USD MILLION)
TABLE 214. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 215. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2017-2032 (USD MILLION)
TABLE 216. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2017-2032 (USD MILLION)
TABLE 217. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 218. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 219. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2017-2032 (USD MILLION)
TABLE 220. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 221. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 222. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 223. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 224. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2017-2032 (USD MILLION)
TABLE 225. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2017-2032 (USD MILLION)
TABLE 226. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 227. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2017-2032 (USD MILLION)
TABLE 228. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2017-2032 (USD MILLION)
TABLE 229. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 230. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 231. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2017-2032 (USD MILLION)
TABLE 232. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 233. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 234. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 235. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 236. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 237. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2017-2032 (USD MILLION)
TABLE 238. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2017-2032 (USD MILLION)
TABLE 239. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 240. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2017-2032 (USD MILLION)
TABLE 241. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2017-2032 (USD MILLION)
TABLE 242. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 243. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 244. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2017-2032 (USD MILLION)
TABLE 245. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 246. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 247. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 248. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 249. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2017-2032 (USD MILLION)
TABLE 250. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2017-2032 (USD MILLION)
TABLE 251. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 252. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2017-2032 (USD MILLION)
TABLE 253. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2017-2032 (USD MILLION)
TABLE 254. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 255. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 256. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2017-2032 (USD MILLION)
TABLE 257. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 258. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 259. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 260. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 261. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2017-2032 (USD MILLION)
TABLE 262. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2017-2032 (USD MILLION)
TABLE 263. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 264. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2017-2032 (USD MILLION)
TABLE 265. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2017-2032 (USD MILLION)
TABLE 266. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 267. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 268. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2017-2032 (USD MILLION)
TABLE 269. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 270. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 271. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 272. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 273. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2017-2032 (USD MILLION)
TABLE 274. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2017-2032 (USD MILLION)
TABLE 275. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 276. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2017-2032 (USD MILLION)
TABLE 277. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2017-2032 (USD MILLION)
TABLE 278. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 279. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 280. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2017-2032 (USD MILLION)
TABLE 281. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 282. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 283. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 284. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 285. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2017-2032 (USD MILLION)
TABLE 286. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2017-2032 (USD MILLION)
TABLE 287. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 288. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2017-2032 (USD MILLION)
TABLE 289. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2017-2032 (USD MILLION)
TABLE 290. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 291. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 292. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2017-2032 (USD MILLION)
TABLE 293. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 294. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 295. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 296. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 297. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2017-2032 (USD MILLION)
TABLE 298. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2017-2032 (USD MILLION)
TABLE 299. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 300. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2017-2032 (USD MILLION)
TABLE 301. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2017-2032 (USD MILLION)
TABLE 302. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 303. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 304. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2017-2032 (USD MILLION)
TABLE 305. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 306. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 307. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 308. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 309. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2017-2032 (USD MILLION)
TABLE 310. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2017-2032 (USD MILLION)
TABLE 311. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 312. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2017-2032 (USD MILLION)
TABLE 313. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2017-2032 (USD MILLION)
TABLE 314. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 315. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 316. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2017-2032 (USD MILLION)
TABLE 317. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 318. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 319. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 320. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 321. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2017-2032 (USD MILLION)
TABLE 322. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2017-2032 (USD MILLION)
TABLE 323. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 324. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2017-2032 (USD MILLION)
TABLE 325. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2017-2032 (USD MILLION)
TABLE 326. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 327. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 328. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2017-2032 (USD MILLION)
TABLE 329. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 330. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 331. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 332. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 333. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2017-2032 (USD MILLION)
TABLE 334. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2017-2032 (USD MILLION)
TABLE 335. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 336. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2017-2032 (USD MILLION)
TABLE 337. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2017-2032 (USD MILLION)
TABLE 338. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 339. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 340. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2017-2032 (USD MILLION)
TABLE 341. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 342. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 343. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 344. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 345. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2017-2032 (USD MILLION)
TABLE 346. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2017-2032 (USD MILLION)
TABLE 347. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 348. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2017-2032 (USD MILLION)
TABLE 349. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2017-2032 (USD MILLION)
TABLE 350. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 351. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 352. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2017-2032 (USD MILLION)
TABLE

Companies Mentioned

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biocartis Group NV
  • bioMérieux SA
  • Bruker Corporation.
  • Creative Diagnostics
  • Danaher Corporation
  • DiaSorin S.p.A.
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corporation
  • Hologic, Inc.
  • Kindstar Globalgene Technology, Inc.
  • Lionex GmbH
  • Molbio Diagnostics Limited
  • QIAGEN N.V.
  • Revvity, Inc.
  • SD Biosensor, Inc.
  • Seegene Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Zhejiang Di'an Diagnostics Technology Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages197
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.59 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.88 Billion
Compound Annual Growth Rate6.7%
Regions CoveredGlobal
No. of Companies Mentioned22

Related Topics

Related Reports

Tuberculosis Testing Market - Global Forecast 2026-2032 - Product Image

Tuberculosis Testing Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Tuberculosis Diagnostics Market Size, Share, Trends and Forecast by Disease Stage, Test Type, End-User, and Region, 2026-2034 - Product Image

Tuberculosis Diagnostics Market Size, Share, Trends and Forecast by Disease Stage, Test Type, End-User, and Region, 2026-2034

  • Report
  • 137 Pages
  • Global
From
Tuberculosis Diagnostics Market Report 2026 - Product Image

Tuberculosis Diagnostics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Tuberculosis Diagnostics - Global Strategic Business Report - Product Image

Tuberculosis Diagnostics - Global Strategic Business Report

  • Report
  • 284 Pages
  • Global
From
Latent Tuberculosis Infection Detection Market Size, Share & Trends Analysis Report by Brand, Test, Application, End Use, Region, and Segment Forecasts, 2026-2033 - Product Image

Latent Tuberculosis Infection Detection Market Size, Share & Trends Analysis Report by Brand, Test, Application, End Use, Region, and Segment Forecasts, 2026-2033

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.